1390654-28-0Relevant academic research and scientific papers
13-(2-methylbenzyl) berberine is a more potent inhibitor of MexXY-dependent aminoglycoside resistance than berberine
Kotani, Kenta,Matsumura, Mio,Morita, Yuji,Tomida, Junko,Kutsuna, Ryo,Nishino, Kunihiko,Yasuike, Shuji,Kawamura, Yoshiaki
, (2019/11/14)
We previously showed that berberine attenuates MexXY efflux-dependent aminoglycoside resistance in Pseudomonas aeruginosa. Here, we aimed to synthesize berberine derivatives with higher MexXY inhibitory activities. We synthesized 11 berberine derivatives, of which 13-(2-methylbenzyl) berberine (13-o-MBB) but not its regiomers showed the most promising MexXY inhibitory activity. 13-o-MBB reduced the minimum inhibitory concentrations (MICs) of various aminoglycosides 4- to 128 fold for a highly multidrug resistant P. aeruginosa strain. Moreover, 13-o-MBB significantly reduced the MICs of gentamicin and amikacin in Achromobacter xylosoxidans and Burkholderia cepacia. The fractional inhibitory concentration indices indicated that 13-o-MBB acted synergistically with aminoglycosides in only MexXY-positive P. aeruginosa strains. Time-kill curves showed that 13-o-MBB or higher concentrations of berberine increased the bactericidal activity of gentamicin by inhibiting MexXY in P. aeruginosa. Our findings indicate that 13-o-MBB inhibits MexXY-dependent aminoglycoside drug resistance more strongly than berberine and that 13-o-MBB is a useful inhibitor of aminoglycoside drug resistance due to MexXY.
Novel 8-Oxoprotoberberine Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor and Pharmaceutical Composition for Preventing or Treating Diseases Associated with Activity of NFAT5, Containing Same as Active Ingredient
-
Paragraph 0140; 0141, (2016/09/26)
The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.
Novel 8-oxoprotoberberine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of diseases induced by activation of NFAT5 containing the same as an active ingredient
-
Paragraph 0132-0135, (2016/10/27)
The present invention relates to: novel 8-oxoprotoberberine derivatives or pharmaceutically acceptable salts thereof; a method for preparing same; and a pharmaceutical composition containing the same as active ingredient for preventing or treating diseases related to NFAT5 activity. According to the present invention, the novel 8-oxoprotoberberine derivatives or the pharmaceutically acceptable salts thereof is proven to: have an oral absorption rate which is significantly higher thatn than of the prior protoberberine; inhibit NFAT5 activity and secretion of inflammatory cyotokine by directly inhibiting transcription of NFAT5; and reduce expression of NFAT5 in a mouse with rheumarthritis. Therefore, the novel 8-oxoprotoberberine derivatives or the pharmaceutically acceptable salts thereof can be advantageously used as a pharmaceutical composition for preventing or treating NFTA5 activity-related diseases, particularly rheumarthritis or inflammation disease.(AA) Days after immune response induction(BB) Control group(CC) Example 1COPYRIGHT KIPO 2015
Structural optimization of berberine as a synergist to restore antifungal activity of fluconazole against drug-resistant Candida albicans
Liu, Hong,Wang, Liang,Li, Yan,Liu, Jiang,An, Maomao,Zhu, Shaolong,Cao, Yongbing,Jiang, Zhihui,Zhao, Mingzhu,Cai, Zhan,Dai, Li,Ni, Tingjunhong,Liu, Wei,Chen, Simin,Wei, Changqing,Zang, Chengxu,Tian, Shujuan,Yang, Jingyu,Wu, Chunfu,Zhang, Dazhi,Liu, Hua,Jiang, Yuanying
, p. 207 - 216 (2014/01/17)
We have conducted systematic structural modification, deconstruction, and reconstruction of the berberine core with the aim of lowering its cytotoxicity, investigating its pharmacophore, and ultimately, seeking novel synergistic agents to restore the effectiveness of fluconazole against fluconazole-resistant Candida albicans. A structure-activity relationship study of 95 analogues led us to identify the novel scaffold of N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-2- (substituted phenyl)acetamides 7 a-l, which exhibited remarkable levels of in vitro synergistic antifungal activity. Compound 7 d (N-(2-(benzo[d][1,3]dioxol- 5-yl)ethyl)-2-(2-fluorophenyl)acetamide) significantly decreased the MIC 80 values of fluconazole from 128.0 μg mL-1 to 0.5 μg mL-1 against fluconazole-resistant C. albicans and exhibited much lower levels of cytotoxicity than berberine toward human umbilical vein endothelial cells. Build it better: Structural optimization of berberine led to the identification of the novel scaffold of N-(2-(benzo[d][1,3]dioxol-5-yl) ethyl)-2-(substituted phenyl)acetamides 7 a-l, which exhibited remarkable in vitro synergistic antifungal activity against fluconazole-resistant Candida albicans in combination with fluconazole. Compound 7 d exhibited much lower cytotoxicity than berberine toward human umbilical vein endothelial cells. Copyright
